Rational Design of a New RXR Agonist Scaffold Enabling Single-Subtype Preference for RXRα, RXRβ, and RXRγ.
暂无分享,去创建一个
M. Schubert-Zsilavecz | A. Chaikuad | D. Merk | J. Marschner | Laura Isigkeit | Gustave Adouvi | Úrsula López-García
[1] S. Graham,et al. Retinoid X Receptor: Cellular and Biochemical Roles of Nuclear Receptor with a Focus on Neuropathological Involvement , 2022, Molecular Neurobiology.
[2] K. Hase,et al. A Retinoid X Receptor Agonist Directed to the Large Intestine Ameliorates T-Cell-Mediated Colitis in Mice , 2021, Frontiers in Pharmacology.
[3] Diogo Santos-Martins,et al. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings , 2021, J. Chem. Inf. Model..
[4] S. Knapp,et al. Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics. , 2021, Journal of medicinal chemistry.
[5] A. Chaikuad,et al. Comprehensive Set of Tertiary Complex Structures and Palmitic Acid Binding Provide Molecular Insights into Ligand Design for RXR Isoforms , 2020, International journal of molecular sciences.
[6] Yang Lu,et al. A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats , 2020, Pharmaceutics.
[7] S. Knapp,et al. L-thyroxin and the non-classical thyroid hormone TETRAC are potent activators of PPARγ. , 2020, Journal of medicinal chemistry.
[8] A. Kalgutkar. Designing Around Structural Alerts in Drug Discovery. , 2020, Journal of medicinal chemistry.
[9] S. Knapp,et al. A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences. , 2019, ACS medicinal chemistry letters.
[10] D. Merk,et al. Therapeutic modulation of retinoid X receptors – SAR and therapeutic potential of RXR ligands and recent patents , 2019, Expert opinion on therapeutic patents.
[11] M. Makishima,et al. A partial agonist for retinoid X receptor mitigates experimental colitis , 2019, International immunology.
[12] E. Proschak,et al. Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation. , 2019, Journal of medicinal chemistry.
[13] E. Proschak,et al. Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype. , 2019, ACS medicinal chemistry letters.
[14] Gisbert Schneider,et al. Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics. , 2018, Journal of medicinal chemistry.
[15] H. Kakuta,et al. Retinoid X Receptor Antagonists , 2018, International journal of molecular sciences.
[16] Ewgenij Proschak,et al. Nonacidic Farnesoid X Receptor Modulators. , 2017, Journal of medicinal chemistry.
[17] Daniel Moser,et al. DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators. , 2017, Bioorganic & medicinal chemistry letters.
[18] K. K. Nanda,et al. Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's Disease. , 2016, Journal of medicinal chemistry.
[19] D. Steinhilber,et al. NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor , 2015, Scientific Reports.
[20] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[21] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[22] R. Evans,et al. Nuclear Receptors, RXR, and the Big Bang , 2014, Cell.
[23] H. Kakuta,et al. Retinoid X receptor ligands: a patent review (2007 – 2013) , 2014, Expert opinion on therapeutic patents.
[24] M. Lazar,et al. Forming functional fat: a growing understanding of adipocyte differentiation , 2011, Nature Reviews Molecular Cell Biology.
[25] A. Stepan,et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.
[26] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[27] Thomas E. Exner,et al. Influence of Protonation, Tautomeric, and Stereoisomeric States on Protein-Ligand Docking Results , 2009, J. Chem. Inf. Model..
[28] J. Romijn,et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. , 2009, Endocrinology.
[29] H. Katinger,et al. Telomerase immortalized human amnion- and adipose-derived mesenchymal stem cells: maintenance of differentiation and immunomodulatory characteristics. , 2009, Tissue engineering. Part A.
[30] M. Makishima,et al. The First Potent Subtype‐Selective Retinoid X Receptor (RXR) Agonist Possessing a 3‐Isopropoxy‐4‐isopropylphenylamino Moiety, NEt‐3IP (RXRα/β‐dual agonist) , 2008, ChemMedChem.
[31] Lucia Altucci,et al. Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.
[32] M. van Griensven,et al. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. , 2007, Tissue engineering.
[33] Gregor Eichele,et al. International Union of Pharmacology. LXIII. Retinoid X Receptors , 2006, Pharmacological Reviews.
[34] M. Schubert-Zsilavecz,et al. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. , 2006, Planta medica.
[35] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[36] K. Hymes,et al. Bexarotene: a clinical review , 2004, Expert review of anticancer therapy.
[37] Igor V. Tetko,et al. Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program , 2002, J. Chem. Inf. Comput. Sci..
[38] M. Boehm,et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. , 1995, Journal of medicinal chemistry.